217 related articles for article (PubMed ID: 29272720)
1. Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.
Nieto J; Alvar J; Rodríguez C; San Andrés MI; San Andrés MD; González F
Res Vet Sci; 2018 Apr; 117():125-132. PubMed ID: 29272720
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.
Usman F; Nopparat J; Javed I; Srichana T
Drug Deliv Transl Res; 2020 Feb; 10(1):59-69. PubMed ID: 31368043
[TBL] [Abstract][Full Text] [Related]
3. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.
Bekersky I; Boswell GW; Hiles R; Fielding RM; Buell D; Walsh TJ
Pharm Res; 1999 Nov; 16(11):1694-701. PubMed ID: 10571274
[TBL] [Abstract][Full Text] [Related]
4. Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits.
Clemons KV; Sobel RA; Williams PL; Stevens DA
Antimicrob Agents Chemother; 2001 Feb; 45(2):612-5. PubMed ID: 11158765
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
[TBL] [Abstract][Full Text] [Related]
6. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
[TBL] [Abstract][Full Text] [Related]
7. A novel delivery system for amphotericin B with lipid nano-sphere (LNS).
Fukui H; Koike T; Saheki A; Sonoke S; Seki J
Int J Pharm; 2003 Oct; 265(1-2):37-45. PubMed ID: 14522116
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
[TBL] [Abstract][Full Text] [Related]
9. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
10. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
11. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
[TBL] [Abstract][Full Text] [Related]
12. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.
Risovic V; Boyd M; Choo E; Wasan KM
Antimicrob Agents Chemother; 2003 Oct; 47(10):3339-42. PubMed ID: 14506053
[TBL] [Abstract][Full Text] [Related]
13. Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B.
Kaji Y; Yamamoto E; Hiraoka T; Oshika T
Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):549-53. PubMed ID: 19043733
[TBL] [Abstract][Full Text] [Related]
14. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs.
Bingöl B; Bakirel T
J Vet Pharmacol Ther; 2018 Feb; 41(1):e16-e21. PubMed ID: 28815733
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS).
Fukui H; Koike T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Sep; 263(1-2):51-60. PubMed ID: 12954180
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid.
Shadkchan Y; Zaslavsky Z; Segal E
Med Mycol; 2003 Feb; 41(1):15-9. PubMed ID: 12627800
[TBL] [Abstract][Full Text] [Related]
19. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.
Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM
Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233
[TBL] [Abstract][Full Text] [Related]
20. Study of the toxicity of a new lipid complex formulation of amphotericin B.
Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
